KRAS and colorectal carcinoma: Studies with preclinical models showed that single-agent KRAS G12C inhibition in this CRC context produced an immediate upregulation of EGFR, leading to the development of dual-blockade therapeutic strategies with the addition of an EGFR-directed monoclonal antibody [24].